标题
Breakthroughs in therapies for NASH and remaining challenges
作者
关键词
steatohepatitis, fibrosis, randomized controlled trials, non-invasive diagnosis, digital pathology, artificial intelligence, trial end-points, diabetes, obesity, cirrhosis, hepatocellular carcinoma
出版物
JOURNAL OF HEPATOLOGY
Volume 76, Issue 6, Pages 1263-1278
出版商
Elsevier BV
发表日期
2022-05-16
DOI
10.1016/j.jhep.2022.04.002
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD
- (2022) Elizabeth M. Brunt et al. JOURNAL OF HEPATOLOGY
- Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project
- (2022) Arun J. Sanyal et al. NATURE MEDICINE
- A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
- (2022) Christopher L. Bowlus et al. JOURNAL OF HEPATOLOGY
- A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
- (2021) Jörn M. Schattenberg et al. JOURNAL OF HEPATOLOGY
- The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
- (2021) Manal F. Abdelmalek et al. Contemporary Clinical Trials
- A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
- (2021) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial
- (2021) Bettina Geidl-Flueck et al. JOURNAL OF HEPATOLOGY
- Therapeutic pipeline in nonalcoholic steatohepatitis
- (2021) Raj Vuppalanchi et al. Nature Reviews Gastroenterology & Hepatology
- Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis
- (2021) Andrea Dennis et al. Frontiers in Endocrinology
- Mechanisms and disease consequences of nonalcoholic fatty liver disease
- (2021) Rohit Loomba et al. CELL
- Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double‐Blind Phase 2 Trial
- (2021) Samer Gawrieh et al. HEPATOLOGY
- Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis
- (2021) Emmanuel Anandraj Selvaraj et al. JOURNAL OF HEPATOLOGY
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
- (2021) Lone B Enebo et al. LANCET
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
- (2021) Rohit Loomba et al. GASTROENTEROLOGY
- Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis
- (2021) Raj Vuppalanchi et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- PPAR‐γ‐induced Changes in Visceral Fat and Adiponectin Levels are Associated with Improvement of Steatohepatitis in Patients with NASH
- (2021) Amalia Gastaldelli et al. LIVER INTERNATIONAL
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
- (2021) Stephen A. Harrison et al. NATURE MEDICINE
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
- (2021) Marco Arrese et al. SEMINARS IN LIVER DISEASE
- Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
- (2021) Martin Bossart et al. Cell Metabolism
- Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
- (2021) V. Ratziu et al. NATURE MEDICINE
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
- (2021) Sven M. Francque et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
- (2021) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis
- (2021) Rohit Loomba et al. GASTROENTEROLOGY
- Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study
- (2021) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease
- (2021) Panu K. Luukkonen et al. JOURNAL OF HEPATOLOGY
- EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
- (2021) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease
- (2020) Stefano Romeo et al. Cell Metabolism
- Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
- (2020) Rod S. Taylor et al. GASTROENTEROLOGY
- Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
- (2020) Vlad Ratziu et al. HEPATOLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
- (2020) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
- (2020) Mark L. Hartman et al. DIABETES CARE
- Why do so many NASH trials fail?
- (2020) Vlad Ratziu et al. GASTROENTEROLOGY
- Alanine Aminotransferase and Gamma Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis
- (2020) Kimberly P. Newton et al. HEPATOLOGY
- Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
- (2020) Sander Lefere et al. JOURNAL OF HEPATOLOGY
- Real-World Burden of Nonalcoholic Steatohepatitis
- (2020) Andreas Geier et al. Clinical Gastroenterology and Hepatology
- Utilization of a Deep Learning Algorithm for Microscope-Based Fatty Vacuole Quantification in a Fatty Liver Model in Mice
- (2020) Yuval Ramot et al. TOXICOLOGIC PATHOLOGY
- Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
- (2020) Rohit Loomba et al. Lancet Gastroenterology & Hepatology
- A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study
- (2020) Stephen A Harrison et al. Lancet Gastroenterology & Hepatology
- Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
- (2020) Tracey G Simon et al. GUT
- Nonalcoholic Steatohepatitis: Current Thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration
- (2020) Frank A. Anania et al. HEPATOLOGY
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
- (2020) Rohit Loomba et al. HEPATOLOGY
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis
- (2020) Mohammad Shadab Siddiqui et al. Clinical Gastroenterology and Hepatology
- Diagnostic Accuracy of Non-Invasive Fibrosis Models to Detect Change in Fibrosis Stage
- (2019) M. Shadab Siddiqui et al. Clinical Gastroenterology and Hepatology
- The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
- (2019) Arun J. Sanyal et al. HEPATOLOGY
- Outcomes of Liver Transplantation for Non-alcoholic Steatohepatitis: a European Liver Transplant Registry Study
- (2019) Debashis Haldar et al. JOURNAL OF HEPATOLOGY
- Past, present and future perspectives in nonalcoholic fatty liver disease
- (2019) Arun J. Sanyal Nature Reviews Gastroenterology & Hepatology
- REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
- (2019) Vlad Ratziu et al. Contemporary Clinical Trials
- Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy
- (2019) Yan Wang et al. GUT
- Liver transplantation for non-alcoholic steatohepatitis in Europe: Where do we stand?
- (2019) François Durand et al. JOURNAL OF HEPATOLOGY
- qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis
- (2019) Feng Liu et al. HEPATOLOGY
- Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Non‐alcoholic Fatty Liver Disease
- (2019) Fasiha Kanwal et al. HEPATOLOGY
- Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis
- (2019) Fernando Bril et al. JOURNAL OF HEPATOLOGY
- Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
- (2019) Naga Chalasani et al. GASTROENTEROLOGY
- Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
- (2019) Guadalupe Garcia-Tsao et al. JOURNAL OF HEPATOLOGY
- A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Vibration-controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease
- (2018) Mohammad S. Siddiqui et al. Clinical Gastroenterology and Hepatology
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation
- (2018) Samar H Ibrahim et al. GUT
- Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data from a Large US Claims Database
- (2018) Alina M. Allen et al. HEPATOLOGY
- Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population
- (2018) Fredrik Åberg et al. HEPATOLOGY
- Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials
- (2018) Cyrielle Caussy et al. HEPATOLOGY
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- PPARγ deacetylation dissociates thiazolidinedione’s metabolic benefits from its adverse effects
- (2018) Michael J. Kraakman et al. JOURNAL OF CLINICAL INVESTIGATION
- Fructose and sugar: A major mediator of non-alcoholic fatty liver disease
- (2018) Thomas Jensen et al. JOURNAL OF HEPATOLOGY
- Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate
- (2018) Benaïssa Boubia et al. JOURNAL OF MEDICINAL CHEMISTRY
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Deciphering the Roles of PPARγ in Adipocytes via Dynamic Change of Transcription Complex
- (2018) Xinran Ma et al. Frontiers in Endocrinology
- Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease
- (2018) Fasiha Kanwal et al. GASTROENTEROLOGY
- GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation
- (2017) David Goldberg et al. GASTROENTEROLOGY
- Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis
- (2017) Michael S. Middleton et al. GASTROENTEROLOGY
- Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
- (2017) Oscar Chávez-Talavera et al. GASTROENTEROLOGY
- High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men
- (2017) Hannes Hagström et al. GUT
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
- (2017) Rohit Loomba et al. HEPATOLOGY
- Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis
- (2017) Yan Wang et al. HEPATOLOGY
- Liver fibrosis scores predict liver disease mortality in the United States population
- (2017) Aynur Unalp-Arida et al. HEPATOLOGY
- Distinct but complementary contributions of PPAR isotypes to energy homeostasis
- (2017) Vanessa Dubois et al. JOURNAL OF CLINICAL INVESTIGATION
- Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis
- (2017) Thomas Karlas et al. JOURNAL OF HEPATOLOGY
- The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
- (2017) Philipp Schwabl et al. JOURNAL OF HEPATOLOGY
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
- (2016) Amalia Gastaldelli et al. HEPATOLOGY
- Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort
- (2016) Veronica Wendy Setiawan et al. HEPATOLOGY
- Thyroid Function and the Risk of Nonalcoholic Fatty Liver Disease: The Rotterdam Study
- (2016) Arjola Bano et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Million Veteran Program: A mega-biobank to study genetic influences on health and disease
- (2016) John Michael Gaziano et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study
- (2016) Hannes Hagström et al. JOURNAL OF HEPATOLOGY
- Type 2 diabetes and risk of hospital admission or death for chronic liver diseases
- (2016) Sarah H. Wild et al. JOURNAL OF HEPATOLOGY
- Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease
- (2016) Jérôme Boursier et al. JOURNAL OF HEPATOLOGY
- Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease
- (2016) Michael Pavlides et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
- (2016) Len Verbeke et al. Scientific Reports
- The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats
- (2015) Len Verbeke et al. AMERICAN JOURNAL OF PATHOLOGY
- Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
- (2015) Robert J. Wong et al. GASTROENTEROLOGY
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- (2015) Paul Angulo et al. GASTROENTEROLOGY
- Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop
- (2015) Arun J. Sanyal et al. HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease
- (2014) L. Fedchuk et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes
- (2014) Raymond E. Soccio et al. Cell Metabolism
- The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease
- (2014) Rifaat Safadi et al. Clinical Gastroenterology and Hepatology
- Repair-Related Activation of Hedgehog Signaling in Stromal Cells Promotes Intrahepatic Hypothyroidism
- (2014) Brittany N. Bohinc et al. ENDOCRINOLOGY
- Roles for Chemokines in Liver Disease
- (2014) Fabio Marra et al. GASTROENTEROLOGY
- Obesity and hepatocellular carcinoma: Hype and reality
- (2014) Hashem B. El-Serag et al. HEPATOLOGY
- qFibrosis: A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients
- (2014) Shuoyu Xu et al. JOURNAL OF HEPATOLOGY
- Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist
- (2013) Rebecca Taub et al. ATHEROSCLEROSIS
- A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials
- (2013) H P Selker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease
- (2013) Jennifer E. Lambert et al. GASTROENTEROLOGY
- Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats
- (2013) Len Verbeke et al. HEPATOLOGY
- Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease
- (2013) Rajarshi Banerjee et al. JOURNAL OF HEPATOLOGY
- Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins
- (2013) Jerry R. Colca et al. PLoS One
- Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
- (2012) Kenneth Cusi GASTROENTEROLOGY
- Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease: A prospective case-control study
- (2012) Lei Xu et al. JOURNAL OF HEPATOLOGY
- Thiazolidinediones and PPARγ agonists: time for a reassessment
- (2012) Bertrand Cariou et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Roles of PPARs in NAFLD: Potential therapeutic targets
- (2011) Anne Tailleux et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Fatty Acid Bile Acid Conjugate Inhibits Hepatic Stearoyl Coenzyme A Desaturase and Is Non-atherogenic
- (2010) Alicia Leikin-Frenkel et al. ARCHIVES OF MEDICAL RESEARCH
- Fibrosing NASH: On Being a Blind Man in a Dark Room Looking for a Black Cat (That Isn't There)
- (2010) Michael R. Charlton GASTROENTEROLOGY
- Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease
- (2010) Brent A. Neuschwander-Tetri et al. HEPATOLOGY
- Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings
- (2010) Elizabeth M. Brunt et al. HEPATOLOGY
- Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis
- (2010) Judith Ertle et al. INTERNATIONAL JOURNAL OF CANCER
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
- (2008) Guruprasad P. Aithal et al. GASTROENTEROLOGY
- Liver biopsy
- (2008) Don C. Rockey et al. HEPATOLOGY
- Impact of Fatty Liver Disease on Health Care Utilization and Costs in a General Population: A 5-Year Observation
- (2007) Sebastian E. Baumeister et al. GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now